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Abstract
Background: Several evidences suggest that failure of synaptic function occurs at preclinical stages of
Alzheimer’s disease (AD) preceding neuronal loss and the classical AD pathological hallmarks. Nowadays, there
is an urgent need to identify reliable biomarkers that could be obtained with non-invasive methods to
improve AD diagnosis at early stages. Here, we have examined plasma levels of a group of miRNAs related to
synaptic proteins in a cohort composed of cognitive healthy controls (HC), mild cognitive impairment (MCI)
and AD subjects.
Methods: Plasma and brain levels of miRNAs were analysed in two different cohorts including 38 HC, 26 MCI,
56 AD dementia patients and 27 frontotemporal dementia (FTD) patients. D’Agostino and Pearson and
Shapiro-Wilk tests were used to evaluate data normality. miRNA levels between groups were compared using
a two-sided nonparametric Mann-Whitney test and sensitivity and specificity was determined by receiver
operating characteristic curve analysis.
Results: Significant upregulation of miR-92a-3p, miR-181c-5p and miR-210-3p was found in the plasma of
both MCI and AD subjects. MCI patients that progress to AD showed higher plasma levels of these miRNAs.
By contrast, no changes in miR-92a-3p, miR-181c-5p or miR-210-3p levels were observed in plasma obtained
from a cohort of FTD.
Conclusion: Our study shows that plasma miR-92a-3p, miR-181c-5p and miR-210-3p constitute a specific
molecular signature potentially useful as a potential biomarker for AD.
Keywords: Alzheimer’s disease, Mild cognitive impairment, Synapses, miRNAs, Plasma, Human, Biomarker,
Frontotemporal dementia
Background
It is estimated that more than 40 million people world-
wide are affected by Alzheimer’s disease (AD) and it is ex-
pected that about 100 million could be affected by 2050.
Unfortunately, there is no treatment to prevent or even
reverse AD, making the finding of new therapeutic break-
throughs a huge challenge for our societies [1]. During the
last decade, much effort has been devoted to the establish-
ment of early AD biomarkers that could help to
implement appropriate personalised care programmes be-
fore the onset of neurodegeneration and dementia. More-
over, effective early AD biomarkers could improve the
design of clinical trials and help to reverse the continuous
failures in the search of disease-modifying agents for AD
obtained in the last years [2–4].
The best AD biomarkers achieved to date are based on
neuroimaging methods (Aβ in the brain or hippocampal
atrophy) or by the detection in the cerebrospinal fluid
(CSF) of total tau, phospho-tau and Aβ42 [5–8]. Re-
cently, a specific roadmap has been suggested to validate
these neuroimaging- and CSF-derived biomarkers [9].
Unfortunately, all these potential biomarkers could not
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be used in routine clinical screening due to their inva-
siveness and economic limitations.
On the other hand, several evidences indicate that cog-
nitive impairment observed in early stages of AD could be
explained by alterations in synaptic function that precedes
neurodegeneration [10]. Furthermore, some reports have
shown that deregulation of synaptic proteins could be re-
lated to early cognitive dysfunction in experimental
models of AD [11–14]. Thus, changes in the regulatory
mechanisms involved in the expression of synaptic pro-
teins could be valuable for assessing prognosis and the
rate of cognitive decline in AD.
MicroRNAs (miRNAs) are small non-coding RNAs that
play a significant role in local control of mRNA translation.
In fact, a single miRNA could regulate the local expression
of multiple proteins. Several studies have shown that some
miRNAs control the formation, maturation and function of
synapses [15] and alteration in their levels could underlie
synaptic dysfunction in pathological states [16]. Notably, a
number of specific miRNAs are misregulated in AD, includ-
ing miRNAs implicated in the regulation of key genes in-
volved in AD, such as APP or BACE1, or neuronal function
such as glutamate receptors [17–20]. Extensive interest has
been focused on identifying changes in specific miRNAs that
could be used as AD biomarkers [21–25]. miRNAs can be
found in the blood where they are transported in different
structures that protect them from degradation [26, 27]. Since
blood collection is an easy and non-invasive procedure, the
identification of blood-based miRNA biomarkers for AD has
drawn attention during the last years [28]. Altered levels of
certain miRNAs in plasma of AD patients have been previ-
ously reported [21, 25, 29–32]; however, few data exist about
changes in plasma levels of miRNAs that are related to syn-
aptic protein function in AD [33]. In the present study, we
have analysed several miRNAs related to synaptic proteins in
plasma samples from mild cognitive impairment (MCI) and
AD subjects. We have also monitored plasma samples from
frontotemporal dementia (FTD) patients to verify the specifi-
city of the obtained results. Our data suggest that
miR-92a-3p, miR-181c-5p and miR-2 10-3p are potential
and specific plasma biomarkers for AD.
Methods
Subjects
Plasma samples analysed in this study were obtained from
two different cohorts. The first cohort provided by Funda-
ció ACE (Barcelona, Spain) includes 14 HC, 26 MCI and
56 AD dementia patients. The second cohort was recruited
at the Memory Unit of the Hospital Sant Pau (Barcelona,
Spain) and consists of 24 HC and 27 FTD patients. Partici-
pants were clinically diagnosed by neurologists and classi-
fied according to internationally accepted diagnostic criteria
[34]. Specifically, MCI subjects fulfilled Petersen’s diagnostic
criteria [35], and their neuropsychological assessment was
done by the previously validated NBACE battery tests [36].
FTD participants include 19 patients with possible or prob-
able behavioural variant [37] and 6 with semantic variant of
primary progressive aphasia [38]. Two patients with FTD
were additionally diagnosed with concomitant ALS accord-
ing to El Escorial criteria [39]. Demographic and clinical
characteristics of cohorts 1 and 2 are summarised in
Table 1. Brain tissue samples were provided by 3 different
Spanish centres: Fundación Cien, Hospital Clinic-IDIBAPS
and Hospital Universitario Fundación Alcorcón. Demo-
graphic and clinical characteristics of the subjects are listed
in Additional file 1: Table S1. Brain tissue from entorhinal
cortex (n = 13), hippocampus (n = 49) and cerebellum (n =
30) was analysed.
Sample processing, RNA extraction and reverse
transcription
Blood samples were collected in EDTA-containing tubes,
as recommended [40]. After 20 min centrifugation
(2500×g), plasma was separated, aliquoted and stored at
− 80 °C until use. Plasma samples were thawed on ice for
RNA extraction, and hemolysis of each sample was ana-
lysed at the time measuring absorbance at 414/375 nm
(414/375 ratio > 1.4 were considered hemolysed) [41].
RNA was isolated from 200 μL of plasma, using the miR-
Neasy RNA isolation kit (Qiagen) following the manu-
facturer’s indications. Two microlitres of RNA was
reverse-transcribed to cDNA using TaqMan™ Advanced
miRNA cDNA Synthesis Kit (Thermo Fisher Scientific).
Table 1 The expression levels of miRNAs related to synaptic proteins
Cohort 1 Cohort 2
HC MCI AD HC FTD
Cohort size 14 26 56 24 27
Men/women 7/7 10/16 15/41 11/13 17/10
Age (years) 68.29 ± 8.99 72.0 ± 8.49 77.77 ± 6.69 67.03 ± 5.05 68.87 ± 7.48
GDS 2.07 ± 0.26 3.15 ± 0.37 4.64 ± 1.02 1 ± 0 3.76 ± 0.99
MMSE 29.21 ± 1.05 26.92 ± 2.22 16.05 ± 7.23 28.5 ± 1.69 25.5 ± 3.76
All data are shown as mean ± SD
HC cognitively healthy controls, MCI mild cognitive impairment, AD Alzheimer’s disease, FTD frontotemporal dementia, MMSE Mini-Mental State Examination, GDS
Global Deterioration Scale
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Postmortem brains were quickly homogenated in dry
ice to prevent thawing, and RNA was isolated from 20 to
50mg of tissue from each brain area using miRVana
miRNA Isolation Kit (Thermo Fisher Scientific) following
the manufacturer’s instructions. RNA quality was evalu-
ated using the Agilent 2100 bioanalyzer. Samples with
RNA integrity number (RIN) under 4 were excluded [40,
42]. Ten nanogrammes of RNA were reverse-transcribed
to cDNA using TaqMan™ MicroRNA Reverse Transcrip-
tion Kit (Thermo Fisher Scientific).
miRNAs quantification by RT-qPCR
Quantitative real-time PCR (RT-qPCR) was performed
from 5 μL of 1/10 diluted cDNA (plasma samples) using
TaqMan Fast Advanced Master Mix and TaqMan Ad-
vanced miRNA Assays (Thermo Fisher Scientific) or
from 1.33 μL of cDNA (tissue samples) using TaqMan™
Universal Master Mix II, with UNG. Applied Biosystems
7500 Fast instrument was used for amplification. Sam-
ples were run in duplicate, and internal control samples
were repeated in every plate to avoid batch effects. Raw
Ct data acquired using the 7500 Software v2.0.6 (Applied
Biosystems) was exported to LinRegPCR software to cal-
culate the amplification efficiency for each reaction. Re-
actions with amplification efficiency below 1.6 were
discarded. Ct values and average efficiencies obtained
from LinRegPCR were used to analyse miRNA levels by
the comparative ΔΔCt method [43]. To date, there is no
consensus on the use of particular reference genes for
miRNA level normalisation in AD studies. Therefore, in
this study, the stability of some described reference
genes was evaluated using the NormFinder algorithm
[44]. hsa-miR-191-5p and hsa-miR-484 were identified
as the most stable reference genes along with all plasma
samples. In addition, hsa-miR-191-5p and hsa-miR-484
showed higher correlation than other candidates (Spear-
man’s correlation coefficient r = 0.89; P < 0.0001). U18
and RNU48 were selected for tissue data normalisation.
miRNA levels were normalised versus the geometric
mean of selected reference genes, to compensate abun-
dance differences between miRNAs and prevent statis-
tical outliers [45].
Western blotting
Human brain tissue was lysed in ice with cold RIPA buf-
fer (50 mM Tris base pH 7.4, 150 mM NaCl, 2 mM
EDTA, 1% NP40, 0.5% Triton X-100, 0.1% SDS, 1 mM
Na3VO4, 25 mM NaF, 1 mM PMSF, 1/100 protease in-
hibitors and 1/100 phosphatases inhibitors cocktail),
sonicated and centrifuged. The supernatant was recov-
ered, and concentration was determined by BCA assay.
An equal amount of protein was loaded in 10–12% poly-
acrylamide gels and separated by electrophoresis under
denaturing conditions (SDS-PAGE). Proteins were then
transferred to nitrocellulose membrane (GE Healthcare),
and membranes were further incubated with blocking
solution (10% dry milk, 0.1% BSA, pH 7.4) for 1 h and
washed with phosphate buffer saline-Tween (PBT-T).
Next, membranes were incubated with primary anti-
bodies (anti-NPTX1 (1:1000, BD), anti-NPTXR (1:500,
Santa Cruz) and anti-b-actin (1:5000, Sigma) overnight
at 4 °C. After washing membranes with PBT-T, they were
incubated at room temperature for 1 h with secondary
peroxidase-coupled antibodies (mouse or rabbit as
needed) prepared in blocking solution. After repeated
washes, proteins were detected by chemoluminescence
reaction using ECL Western Blotting reagent (GE
Healthcare). Immunoblots were analysed by densitom-
etry using ImageJ (National Institutes of Health, Be-
thesda, MD), and protein levels were corrected for
corresponding loading control.
Statistical analysis
Ct values were normalised versus the Ct mean of the
control group and log2 transformed. D’Agostino and
Pearson and Shapiro-Wilk tests were used to evaluate
data normality. miRNA levels from controls, and pa-
tients were compared using a two-sided nonparametric
Mann-Whitney test. Bonferroni correction was applied
for multiple comparisons when needed. Non-parametric
Spearmen’s rank correlation test was used to determine
the correlation between miRNA expression levels and
age. P values < 0.05 were considered statistically signifi-
cant. ROC curve analysis under a nonparametric ap-
proach was used to obtain the area under de curve
(AUC) to evaluate sensitivity and specificity of each
miRNA as a predictive biomarker. Logistic regression
was applied to evaluate biomarker combination by ROC
curve analysis. Statistical analysis was performed using
GraphPad Prism software v6.01 (GraphPad Software
Inc., CA, USA) and MedCalc (v17.9.7).
Results
Upregulation of miR-92a, miR-181c and miR-210 in
plasma of MCI and AD patients
The expression levels of miRNAs related to synaptic
proteins, miR-92a-3p, miR-181c-5p, miR-210-3p and
miR-584-5p (Additional file 1: Table S2), were analysed
by RT-qPCR in the plasma of a cohort consisting of 14
HC, 26 MCI and 56 sporadic AD subjects (Table 1). We
found a significant increase in the levels of miR-92a-3p,
miR-181c-5p and miR-210-3p in plasma from AD pa-
tients when compared with HC (Fig. 1a; miR-92a-3p: P
= 0.0442, log2 fold change = 0.52; miR-181c-5p: P =
0.0024, log2 fold change = 0.67; miR-210-3p: P = 0.0006,
log2 fold change = 0.60). A significant increase was also
observed in MCI plasma samples for miR-181c-5p (P =
0.0004, log2 fold change = 0.80) and miR-210-3p (P =
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Fig. 1 Circulating miRNA levels at different stages of AD pathology compared with cognitively normal controls (a). Log2 transformed data were
normalised versus the geometric mean of miR-191-5p and miR-484 levels. Statistical significance was evaluated by the Mann-Whitney U test
followed by the Bonferroni correction for multiple comparisons. P values < 0.05 were considered statistically significant. b Receiver operating
characteristic (ROC) curve analysis was performed to distinguish MCI (blue) and AD (red) cases from healthy controls. The area under the curve
(AUC) is shown for each miRNA and stage
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0.0276, log2 fold change = 0.49) whereas an increasing
trend was observed for miR-92a-3p (P = 0.0798, log2 fold
change = 0.55). By contrast, no apparent changes were
observed in miR-584-5p expression levels between HC
and MCI or AD subjects (data not shown). Statistical
correlation analysis revealed that those changes were not
due to the increasing age in the MCI and AD groups
(Additional file 1: Figure S2). Also, no differences be-
tween sexes were observed in HC, MCI and AD groups
(Additional file 1: Figure S3).
Next, ROC curve analysis was performed to evaluate
the diagnostic potential of miR-92a-3p, miR-181c-5p
and miR-210-3p (Fig. 1b). The values obtained for
miR-92a-3p, miR-181c-5p and miR-210-3p when HC
were compared with MCI subjects were as follows: AUC
values of 0.67, 0.84 and 0.74, respectively; 50.00%,
84.62% and 76.92% of sensitivity, respectively; and
92.86%, 85.71% and 71.43% of specificity, respectively
(Table 2). AUC values for miR-92a-3p, miR-181c-5p and
miR-210-3p when AD subjects were compared to HC
were 0.70, 0.77 and 0.80, respectively. Whereas
miR-92a-3p has 47.37% of sensitivity and 92.86% of spe-
cificity, miR-181c-5p has 70.18% of sensitivity and
85.71% of specificity and miR-210-3p has 80.70% of sen-
sitivity and 71.43% of specificity (Table 3). ROC curve
analysis using logistic regression for miR-92a-3p,
miR-181c-5p and miR-210-3p combination yielded a
better diagnostic value for MCI and AD, suggesting that
these miRNAs together could be used as a molecular
signature for early diagnosis of MCI and/or AD. We de-
termined an AUC value of 0.893, a sensitivity of 84.62%
and a specificity of 85.71% for distinguishing MCI from
HC (Fig. 2a and Table 2). This molecular miRNA signa-
ture provided an AUC value of 0.855, a sensitivity of
92.86% and a specificity of 71.43% when AD samples
were compared to HC (Fig. 2b and Table 3).
We also looked for eventual sex-dependent differences
in the diagnostic potential of the examined miRNAs
(Fig. 2). We found a slightly better diagnostic value for
men than for women to distinguish MCI from HC sub-
jects (Table 2): (a) the AUC values for women and men
are 0.82 and 0.96 respectively; (b) 87.50% sensitivity for
women and 100% for men; and (c) 71.43% and 85.71%
specificity for women and men, respectively. On the
other hand, the values obtained when comparing AD
with HC subjects indicated a better diagnostic specificity
and a lower sensitivity for men than for women (Table 3):
(a) the AUC values for women and men are 0.82 and
0.94; (b) 90.24% and 75.00% sensitivity for women and
men; and (c) 71.43% and 100% specificity for women
and men, respectively.
In order to provide further support to the value of our
molecular miRNA signature as a molecular biomarker
for early AD diagnosis, we have followed up 19 of the 26
MCI subjects for 1 to 12 years (Additional file 1: Table
S3). Three subjects diagnosed as MCI (11.5%; P4, P8 and
P22) showed no cognitive impairment after 1 (P4 and
P22) or 4 (P8) years, and another two (P14 and P18)
were still diagnosed as MCI after 3 and 11 years. The
rest of the cases, all developed dementia being AD the
most prominent. Only one patient progressed to FTD
(P7) and another to vascular dementia (P11; Add-
itional file 1: Table S3). Interestingly, we have observed
that all the MCI patients that progressed to AD have
higher values of the miRNA signature compared to the
MCI patients that did not evolve to AD (Fig. 3).
Expression levels of miR-92a, miR-181c and miR-210 in
AD brains
To investigate whether the observed changes in
miR-92a-3p, miR-181c-5p and miR-210-3p levels were as-
sociated to changes in the brain, we measured their levels
in the entorhinal cortex, hippocampus and cerebellum from
cognitively normal controls (Braak I/II) and early (Braak
III/IV) and late (Braak V/VI) AD patients (Additional file 1:
Table S1 and Additional file 1: Figure S1). We found that
Table 2 Individual and signature miRNAs performance characteristics in predicting MCI stage. Signature miRNA performance
characteristics in women and men
miRNA/signature AUC Sensitivity % Specificity % Youden Index J P value
miR-92a-3p 0.673 50.00 92.86 0.428 0.0563
miR-181c-5p 0.843 84.62 85.71 0.703 < 0.0001
miR-210-3p 0.736 76.92 71.43 0.483 0.0038
miR-92a-3p/miR-210-3p 0.731 73.08 71.43 0.445 0.0050
miR-92a-3p/miR-181c-5p 0.838 84.62 78.57 0.632 < 0.0001
miR-181c-5p/miR-210-3p 0.865 88.46 78.57 0.670 < 0.0001
miR-92a-3p/miR-181c-5p/ miR-210-3p 0.893 84.62 85.71 0.703 < 0.0001
Women 0.821 87.50 71.43 0.589 0.0005
Men 0.957 100.0 85.71 0.857 < 0.0001
AUC area under the curve
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miR-92a-3p, miR-181c-5p and miR-210-3p levels are
slightly increased in the entorhinal cortex at early and late
AD compared to HC. However, it only reached statistical
significance in the case of miR-92a-3p when compared to
late AD (Braak V-VI; Additional file 1: Figure S1A), prob-
ably due to the small number of samples analysed in this
region. A similar trend was observed for miR-92a-3p and
miR-181c-5p in the hippocampus (Additional file 1: Figure
S1B). No significant changes of miR-210-3p in the hippo-
campus or in miR92a-3p, miR-181c-5p and miR-210-3p in
the cerebellum were observed at any disease stage (Add-
itional file 1: Figure S1B, C). Thus, although there is an
overall trend to increase in the hippocampus and en-
torhinal cortex, it is not possible to conclude that
miRNA changes observed in plasma are related to
those observed in the brain since they lack global
statistical significance. miR-181c-5p has neuronal pen-
traxin 1 (NPTX1) and neuronal pentraxin receptor
(NPTXR) as potential targets. Since miR-181c-5p is
increased in the entorhinal cortex, we next examined
the protein levels of NPTX1 and NPTXR wanted to
check whether this increase coincided with a change
in the levels of these proteins. As shown in
Additional file 1: Figure S3, we observed a decrease
in NPTX1 and NPTXR although it did not reach stat-
istical significance likely due to the low number of
samples.
Expression levels of miR92a, miR181c and miR210 are not
affected in FTD patients
In order to determine whether the changes observed in
miR-92a-3p, miR-181c-5p and miR-210-3p in plasma
were specific of MCI and AD subjects, we decided to
analyse plasma samples from a cohort of FTD patients.
None of the abovementioned miRNAs were altered in
FTD (Fig. 4) suggesting that the changes observed could
be specific for MCI and AD subjects.
Discussion
The search of blood-based biomarkers for early detec-
tion of AD has gained increasing attention during the
last decade due to the non-invasiveness of the procedure
and its low economical costs when compared to the use
of CSF or neuroimaging techniques, which would poten-
tially allow their use in routine tests worldwide. Among
the diversity of molecules and factors that could be ana-
lysed in blood-derived samples, miRNAs represent one
of the most promising approaches to identify peripheral
AD biomarkers [7, 17, 20, 46] since they are relatively
abundant and highly stable in blood.
Several reports have performed miRNAs profiling in
brain and CSF that have identified numerous miRNAs
as potential biomarkers to detect AD [46–49]. Whereas
some studies have focused on miRNAs regulating spe-
cific AD-related proteins, little attention has been de-
voted to miRNAs involved in the regulation of synaptic
proteins. In the present study, we have analysed plasma
levels of specific miRNAs related to the regulation of
synaptic proteins, especially glutamatergic synapses, in
HC, MCI and AD patients. Thus, this work comple-
ments other reports that have suggested the potential of
miRNAs as biomarkers for AD.
From the different miRNAs analysed, we have ob-
served a significant increase in miR-92a-3p,
miR-181c-5p and miR-210-3p plasma levels in MCI and
AD. Moreover, an increase in the levels of these three
miRNAs was observed in AD entorhinal cortex. How-
ever, only miR-92a-3p changes reached statistical signifi-
cance probably due to the low number of available
samples used. No significant changes in hippocampal
levels were observed for miR-181c-5p and miR-210-3p.
Hence, our data adds on many previous reports indicat-
ing that miRNA changes between brain and CSF/plasma
samples do not necessarily run in parallel [22].
Among other targets, miR181c-5p and miR-210-3p
have neuronal pentraxin 1 (NPTX1) and neuronal
Table 3 Individual and signature miRNAs performance characteristics in predicting AD. Signature miRNAs performance
characteristics in women and men
miRNA/signature AUC Sensitivity % Specificity % Youden Index J P value
miR-92a-3p 0.697 47.37 92.86 0.402 0.0124
miR-181c-5p 0.773 70.18 85.71 0.559 < 0.0001
miR-210-3p 0.799 80.70 71.43 0.521 < 0.0001
miR-92a-3p/miR-210-3p 0.807 87.72 64.29 0.520 < 0.0001
miR-92a-3p/miR-181c-5p 0.787 84.21 71.43 0.556 0.0001
miR-181c-5p/miR-210-3p 0.853 84.21 78.57 0.628 < 0.0001
miR-92a-3p/miR-181c-5p/ miR-210-3p 0.855 92.86 71.43 0.644 < 0.0001
Women 0.815 90.24 71.43 0.617 0.0009
Men 0.938 75.0 100.0 0.750 < 0.0001
AUC area under the curve
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pentraxin receptor (NPTXR) as potential targets. Indeed,
it has been described that miR-210-3p regulates the ex-
pression of NPTX1 and NPTXR [50]. These proteins are
involved in the recruitment and clustering of AMPA re-
ceptors in postsynaptic terminals, organising and model-
ling the activity of glutamatergic synapses in the
hippocampus affecting their synaptic plasticity [51, 52].
Thus, an increase of these miRNAs would reduce the
levels of NPTX1 and NPTXR and could contribute to
the glutamatergic synaptic dysfunction and early cogni-
tive impairment present in AD prior to neurodegenera-
tion. In fact, the increase in miR-181c-5p coincided with
a decrease in NPTX1 and NPTXR protein in the ento-
rhinal cortex.
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Fig. 2 miRNAs were combined to reach the best predictive value. ROC curve analysis for MCI (a) and AD (b) cases are shown. Values for men (c,
d) and women (e, f) are represented separately
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Based on the observed increase in miR-92a-3p,
miR-181c-5p and miR-210-3p, we propose that these
miRNAs constitute a molecular signature that could be
used as a biomarker for MCI and AD. The AUC values
of this molecular signature are similar (0.893 accuracy,
84.6% sensitivity and 85.71% sensitivity) to the ones ob-
tained in other studies that have proposed either a
12-miRNA signature that distinguishes MCI with 0.842
accuracy, 81.1% specificity and 87.7% sensitivity in blood
[29] or a 9-miRNAs serum signature for AD cases iden-
tification with an AUC value of 0.978, 93.4% sensitivity
and 98.8% of specificity [53]. Our results are the first
that described an alteration of miR-92a-3p and
miR-210-3p levels in biological fluids from AD patients.
Only a previous report showed that soluble Aβ secreted
from 7PA2 cells produced an increase in miR-210 levels
in a mature primary culture of cortical neurons [54] and
another study by Cogswell and co-workers reported that
the levels of miR-92 were enhanced in AD hippocampus
[47]. On the other hand, the observed increase in
miR-181c-5p in plasma of MCI and AD subjects is chal-
lenged by previous reports reporting opposite observa-
tions. For instance, a decrease in miR-181c levels was
reported in serum [20, 30, 53] and CSF [47] from AD
patients. The causes of these discrepancies are currently
unclear.
We were able to follow up for several years the evolu-
tion of the MCI patients included in our study, and we
observed that the signature values in the plasma of the
MCI patients that progressed to AD were significantly
higher than the values found in the MCI patients that
did not progress to dementia. Thus, plasma levels of
miR-92a-3p, miR-181c-5p and miR-210-3p could not
only be used as a biomarker signature for MCI and AD
but might also indicate whether a patient with MCI will
progress to AD. To our knowledge, this is the first study
in which miRNAs levels in MCI patients are associated
with the diagnosis of AD. However, we are aware that
due to the low number of MCI patients that did not pro-
gress to AD, further studies with more samples should
be done before we can conclude that plasma levels of
miR-92a-3p, miR-181c-5p and miR-210-3p are a good
prognostic signature for the progression from MCI to
AD.
Several studies have shown that AD-associated
changes in miRNAs expression are also found in other
types of dementia such as frontotemporal dementia or
dementia with Lewy bodies [55]. Thus, those miRNAs
could not be considered as eventual specific biomarkers
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for AD. For example, some reports have shown that
miR-132 levels are downregulated in AD [46, 49, 56] and
similar results were obtained in other neurodegenerative dis-
eases [19, 55, 57], suggesting that the alteration of this
miRNA is linked to common pathological mechanisms in
neurodegenerative diseases. In order to know whether this
coincidence was also observed with miR-92a-3p,
miR-181c-5p and miR-210-3p levels, we analysed their levels
in plasma samples from a cohort of FTD patients. The re-
sults obtained indicate that no changes exist in our molecu-
lar miRNA signature between HC and FTD samples,
suggesting that the increase in miR-92a-3p, miR-181c-5p
and miR-210-3p levels could be specific for AD.
The existence of sex differences in AD is well established.
Not only in the prevalence but also in the severity of the dis-
ease progression, being suggested that women could be more
susceptible than men to the neuropathological cascade of
AD [58]. Thus, it has become more necessary to introduce
the effects of sex in the studies [59]. We have analysed
whether differences exist between men and women and we
did not find significant differences between sexes neither in
the levels of the miRNAs nor in their value as a molecular
signature. Only a slightly higher AUC was obtained in men
to predict MCI (0.957 vs 0.821) or AD (0.938 vs 0.815) com-
pared to women. Thus, data from the studied cohort sup-
ports that our miRNA signature would be equally effective
as a biomarker for AD in both men and women.
In summary, this study provides data supporting that a
plasma miRNA signature composed of miR-92a-3p,
miR-181c-5p and miR-210-3p could be useful as a
non-invasive clinical biomarker for diagnosis of AD that
could be used for improving current clinical trials and in fu-
ture therapeutic strategies. Moreover, the levels of these
miRNAs in MCI patients could predict the progression to
AD dementia. Further studies are needed to assess whether
changes in this miRNA signature correlates with known AD
biomarkers. Likewise, obtaining additional data from other
MCI and AD cohorts would be necessary to fully validate
the data presented in this study and to establish this miRNA
signature as a reliable biomarker for early stages of AD.
Conclusions
Deficits in synaptic function are likely to be involved in the
development of AD in its preclinical stages. Here, we have
analysed the levels of specific miRNAs related to synaptic
proteins finding that the levels of miR-92a-3p, miR-181c-5p
and miR-210-3p are deregulated in plasma from MCI and
AD subjects while no changes are observed in plasma from
FTD patients. Moreover, the analysis combining these three
miRNAs yielded high diagnosis accuracy for distinguishing
both MCI and AD subjects from healthy controls and could
also predict MCI progress to AD. Thus, we propose plasma
levels of miR-92a-3p, miR-181c-5p and miR-210-3p as a mo-
lecular signature to be used as a novel biomarker for AD.
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